Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 6/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25757497 | 0.95 | MAPT (0.36) | MAPTMAPK1NPSR1L3MBTL1PRKCD | |
| SCHEMBL25761405 | 0.94 | MAPT (0.35) | MAPTMAPK1NPSR1L3MBTL1PRKCD | |
| SCHEMBL25757485 | 0.92 | MAPT (0.34) | MAPTMAPK1NPSR1L3MBTL1PRKCD | |
| SCHEMBL25758816 | 0.89 | MAPT (0.39) | MAPTMAPK1NPSR1L3MBTL1PRKCD | |
| SCHEMBL25758670 | 0.86 | MAPT (0.37) | MAPTMAPK1NPSR1L3MBTL1PRKCD | |
| SCHEMBL25761358 | 0.83 | CPB2 (0.38) | MAPTMAPK1NPSR1L3MBTL1 | |
| SCHEMBL25757498 | 0.75 | S1PR4 (0.36) | MAPTMAPK1NPSR1L3MBTL1PRKCD | |
| SCHEMBL25757484 | 0.75 | S1PR1 (0.39) | PRKCDACHE | |
| SCHEMBL18641869 | 0.74 | ACHE (0.50) | ACHE | |
| SCHEMBL25545103 | 0.74 | CA1 (0.47) | MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | MAPT 4102/4885MAPK1 4510/4885NPSR1 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.